In short
BI 1839100 is a new drug being studied in clinical trials for its potential in treating pulmonary fibrosis and associated chronic cough. These trials aim to assess the safety, tolerability, and effectiveness of BI 1839100 in healthy individuals and patients with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). The studies range from initial safety assessments in healthy volunteers to more advanced trials evaluating the drug's impact on cough frequency and lung function in patients with pulmonary fibrosis.
At a glance
- Drug Name
- BI 1839100
- Primary Conditions Studied
- Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF)
- Main Study Objectives
- Safety, tolerability, pharmacokinetics, efficacy in reducing cough
- Study Phases
- Phase I (healthy volunteers), Phase IIa/IIb (patients with IPF/PPF)
- Key Outcome Measures
- 24-hour cough frequency, cough severity, lung function (FVC), quality of life
- Study Designs
- Single and multiple rising dose, placebo-controlled, randomized
- Special Assessments
- Drug-drug interactions, effect of food on drug absorption
What is BI 1839100?
BI 1839100 is a new drug currently being developed and tested for its potential to treat certain lung conditions and chronic cough. It is still in the early stages of research, known as clinical trials, where scientists are studying how well it works and how safe it is for patients.
What Conditions Does BI 1839100 Target?
The main conditions that BI 1839100 is being studied for are:
- Idiopathic Pulmonary Fibrosis (IPF): This is a serious lung disease where the tissue in the lungs becomes scarred over time, making it difficult to breathe.
- Progressive Pulmonary Fibrosis (PPF): This refers to various lung conditions where scarring in the lungs gets worse over time.
- Chronic Cough: A persistent cough that lasts for a long time and is often associated with lung conditions like IPF and PPF.
Researchers are particularly interested in how BI 1839100 might help reduce coughing in people with these conditions, which can significantly impact their quality of life.
How Does BI 1839100 Work?
While the exact mechanism of how BI 1839100 works is not fully described in the available information, it appears to target the underlying causes of chronic cough in people with pulmonary fibrosis. The drug is being tested in both oral (taken by mouth) and intravenous (given through a vein) forms.
Current Clinical Trials
Several clinical trials are currently underway to study different aspects of BI 1839100:
- Safety and Tolerability Studies: These trials are testing how well people can tolerate different doses of the drug and what side effects might occur.
- Pharmacokinetic Studies: These look at how the drug moves through the body, including how it's absorbed, distributed, and eliminated.
- Efficacy Studies: A larger trial is testing how well BI 1839100 works in reducing cough in people with IPF or PPF. This study is measuring things like cough frequency, cough severity, and quality of life.
Safety and Tolerability
The safety of BI 1839100 is a primary focus of the ongoing clinical trials. Researchers are carefully monitoring for any side effects or adverse reactions. So far, studies have included healthy volunteers to establish the drug's safety profile before testing it in patients with lung conditions.
One study is even looking at how the drug affects skin sensitivity using a substance called allyl isothiocyanate (AITC), which is commonly found in mustard and wasabi.
Potential Drug Interactions
Researchers are also studying how BI 1839100 might interact with other medications. Specific drugs being tested for interactions include:
- Midazolam: A sedative medication
- Digoxin: A heart medication
- Rosuvastatin: A cholesterol-lowering medication
These studies will help doctors understand if BI 1839100 can be safely taken with other common medications.
Future Prospects
While BI 1839100 is still in the early stages of development, it shows promise for potentially helping people with chronic cough related to pulmonary fibrosis. If the current trials show positive results, it could lead to further studies and potentially become a new treatment option for these challenging conditions.
It's important to note that as a drug in development, BI 1839100 is not yet available for general use. Patients interested in this potential treatment should speak with their healthcare providers about the latest developments and possible clinical trial opportunities.